Explore the vast range of titles available.

Transient osteoporosis of the hip is a rare, temporary condition characterized by hip pain and functional limitations, which can significantly reduce the quality of life. Bone marrow edema of the proximal femur, identified through magnetic resonance imaging is the primary diagnostic feature of transient osteoporosis of the hip. While the exact cause of transient osteoporosis of the hip remains unclear, several potential pathophysiological mechanisms warrant further investigation to better understand this condition. In this case study, we present an unusual case of a patient with transient osteoporosis of the hip who was diagnosed with non-alcoholic fatty liver disease. A 42-year-old Caucasian man presented with left hip pain. After clinical and radiological evaluations, he was diagnosed with transient osteoporosis of the hip. Biochemical assessment revealed a persistent and isolated elevation of alanine aminotransferase. The patient underwent a treatment regimen involving 16 days of intramuscular neridronate along with physical therapy. At the 3- and 6-month follow-ups, he showed significant improvements in both clinical symptoms and radiological findings. In our study, we propose, for the first time, a potential association between liver disorders, specifically non-alcoholic fatty liver disease, and the onset of transient osteoporosis of the hip, exploring the possible pathophysiological mechanisms connecting these two conditions and discuss the rationale for both pharmacological and non-pharmacological treatments.

Background and Objectives: Sport-related musculoskeletal injuries (MSK-Is) are a common health issue in athletes that can lead to reduced performance. The aim of this scoping review was to synthetize available evidence on injury incidence rates (IIRs), types, and sites that affect the musculoskeletal (MSK) system of adult athletes. Materials and Methods: We performed a scoping review on the Pubmed database limiting our search to 33 Olympic sports. Results: We identified a total of 1022 papers, and of these 162 were examined in full for the purpose of this review. Archery was the sport with the highest risk of injuries to the upper extremities, marathons for the lower extremities, and triathlon and weightlifting for the body bust. In the majority of the sports examined, muscle/tendon strain and ligament sprain were the most common MSK-Is diagnoses, while athletics, karate, and football were the sports with the highest IIRs, depending on the methods used for their calculations. Conclusions: Our scoping review highlighted the general lack and dishomogeneity in the collection of data on MSK-Is in athletes.

Background/Objectives: Calcium and magnesium play a key role in musculoskeletal health and neuromuscular function. Mineral waters naturally rich in these elements provide a highly bioavailable dietary source. This study evaluated whether daily intake of naturally calcium and magnesium-rich mineral water compared with low-mineral water affects fall risk, muscle mass, and muscle function in adults aged ≥50 years, with or without osteosarcopenia. Methods: In this 12-month, randomized, double-blind, controlled trial, 98 participants (86.7% women, 13.3% men) were assigned to consume 1 L/day of either SG9 (mineral water with high calcium and magnesium content) or J66 (low-mineral water). Outcomes included incidence of falls (primary endpoint), appendicular skeletal muscle mass (ASMM), muscle strength, physical performance, biochemical markers, and patient-reported measures. Assessments were performed at baseline, 6 months, and 12 months following CONSORT guidelines. Results: Ninety-eight participants (mean age ~63 years) were randomized and completed the 12-month follow-up. At 6 months, the incidence of falls was significantly lower in the SG9 group compared with the J66 group (relative risk reduction 82%; RR = 0.18, 95% CI 0.04–0.88; p < 0.05), whereas no significant between-group difference was observed at 12 months. Appendicular skeletal muscle mass indexed to height (ASMM/h2) was significantly higher in the SG9 group at 12 months (p = 0.0002). In participants with osteosarcopenia, SG9 intake was associated with a consistent improvement in ASMM/h2 at 6 and 12 months (p = 0.004 and p = 0.006, respectively). No significant between-group differences were detected in physical performance scores, biochemical markers, or quality-of-life measures. Conclusions: Daily consumption of calcium- and magnesium rich mineral water reduced fall risk and improved muscle mass in adults over 50 years, with or without osteosarcopenia. These findings support the role of calcium and magnesium-rich mineral water use as a complementary nutritional strategy for musculoskeletal health and fragility prevention.

Osteoporosis and fragility fractures are relevant health issues because of their impact in terms of morbidity, mortality, and socioeconomic burden. Despite this alarming scenario, both underdiagnosis and undertreatment are common features of osteoporotic patients, particularly those who have already sustained a fragility fracture. Pharmacotherapy of osteoporosis is the main treatment option for these patients because of strong evidence about the efficacy of available drugs targeting bone metabolism. However, several issues can interfere with the effectiveness of anti-osteoporotic drugs in clinical practice, such as lack of awareness of both healthcare providers and patients, poor adherence to therapy, and safety in long-term treatment. Therefore, new therapeutic strategies have been proposed to overcome these problems, such as sequential therapy or emerging molecules mainly targeting the stimulation of bone formation. In particular, abaloparatide has been demonstrated to reduce major nonvertebral fracture risk compared with both placebo and teriparatide, although the European Medicines Agency (EMA) refused the marketing authorization because the benefits of this drug did not outweigh its risks. On the other side, EMA has recently approved romosozumab, a monoclonal antibody directed against sclerostin and the only available therapeutic option targeting Wnt signaling, as both bone-forming and antiresorptive intervention to treat osteoporosis and fragility fractures.

Background It has been suggested that overweight and obese individuals have an increased risk to develop vitamin D deficiency, commonly associated with poor muscle performance. The relationship among fat mass, vitamin D status, and skeletal muscle is still debated. Aims To evaluate the effects of the combination of hypovitaminosis D and overweight on muscle mass and strength, and physical performance in post-menopausal women. Methods In this cross-sectional study, we recruited post-menopausal women referring to a physiatric outpatient service for the management of osteoporosis over a 36-month period. We compared four groups: (1) normal weight with hypovitaminosis D; (2) overweight with normal serum 25(OH)D 3 ; (3) overweight with hypovitaminosis D; and (4) normal weight with normal serum 25(OH)D 3 (control group). Outcome measures were: appendicular lean mass-to-BMI ratio; hand grip strength; and short physical performance battery. Results We analysed 368 women (mean aged 67.2 ± 7.8 years): 95 normal weight with hypovitaminosis D, 90 overweight with normal levels of 25(OH)D 3 , 96 overweight with hypovitaminosis D, and 87 normal weight with normal levels of 25(OH)D 3 . Overweight women with hypovitaminosis D had a significant risk of reduced muscle mass (OR 5.70; p  < 0.001), strength (OR 12.05; p  < 0.001), and performance (OR 5.84; p  < 0.001) compared to controls. Normal weight women with hypovitaminosis D had only a greater risk of an impairment of muscle strength (OR 7.30; p  < 0.001) and performance (OR 3.16; p  < 0.001). Discussion According to our findings, both hypovitaminosis D and overweight should be investigated in post-menopausal women because of their negative effects on skeletal muscle mass and function. Conclusions This study demonstrated that hypovitaminosis D is associated to impaired muscle function and its combination with overweight might lead also to muscle wasting in a cohort of post-menopausal women.

The colony-stimulating factor 1 receptor (CSF-1R) plays a pivotal role in orchestrating cellular interactions within the tumor microenvironment (TME). Although the CSF-1R has been extensively studied in myeloid cells, the expression of this receptor and its emerging role in other cell types in the TME need to be further analyzed. This review explores the multifaceted functions of the CSF-1R across various TME cellular populations, including tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), dendritic cells (DCs), cancer-associated fibroblasts (CAFs), endothelial cells (ECs), and cancer stem cells (CSCs). The activation of the CSF-1R by its ligands, colony-stimulating factor 1 (CSF-1) and Interleukin-34 (IL-34), regulates TAM polarization towards an immunosuppressive M2 phenotype, promoting tumor progression and immune evasion. Similarly, CSF-1R signaling influences MDSCs to exert immunosuppressive functions, hindering anti-tumor immunity. In DCs, the CSF-1R alters antigen-presenting capabilities, compromising immune surveillance against cancer cells. CSF-1R expression in CAFs and ECs regulates immune modulation, angiogenesis, and immune cell trafficking within the TME, fostering a pro-tumorigenic milieu. Notably, the CSF-1R in CSCs contributes to tumor aggressiveness and therapeutic resistance through interactions with TAMs and the modulation of stemness features. Understanding the diverse roles of the CSF-1R in the TME underscores its potential as a therapeutic target for cancer treatment, aiming at disrupting pro-tumorigenic cellular crosstalk and enhancing anti-tumor immune responses.

Musculoskeletal disorders are characterized by several impairments, including pain, affecting muscles, bones, joints and adjacent connective tissue, resulting in temporary or permanent functional limitations and disability. Musculoskeletal pain is particularly prevalent worldwide and greatly impacts the quality of life, social participation and economic burden. To date, several issues persist about the classification of musculoskeletal pain and its management strategies and resources. The treatment of musculoskeletal pain conditions is complex and often requires a multimodal approach, including pharmacological and non-pharmacological therapy that might be ineffective in many cases, resulting in poor patient satisfaction and controversial expectations about the potential benefits of available interventions. This manuscript provides an overview of unmet needs in managing musculoskeletal pain, particularly focusing on pharmacotherapeutic pitfalls in this context.

Background The Italian Society for Orthopaedics and Traumatology conceived this guidance—which is primarily addressed to Italian orthopedic surgeons, but should also prove useful to other bone specialists and to general practitioners—in order to improve the diagnosis, prevention, and treatment of osteoporosis and its consequences. Materials and methods Literature reviews by a multidisciplinary team. Results The following topics are covered: the role of instrumental, metabolic, and genetic evaluations in the diagnosis of osteoporosis; appraisal of the risk of fracture and thresholds for intervention; general strategies for the prevention and treatment of osteoporosis (primary and secondary prevention); the pharmacologic treatment of osteoporosis; the setting and implementation of fracture liaison services for tertiary prevention. Grade A, B, and C recommendations are provided based on the main levels of evidence (1–3). Toolboxes for everyday clinical practice are provided. Conclusions The first up-to-date Italian guidelines for the primary, secondary, and tertiary prevention of osteoporosis and osteoporotic fractures are presented.

Osteoporosis (OP) is a chronic disease characterized by reduced bone mass and altered microarchitecture, leading to bone fragility and fractures. Due to its high morbidity, disability, and healthcare costs, identifying new biomarkers and therapeutic strategies is crucial for improving OP diagnosis and prevention. In this context, this narrative review aims to depict the role of carbohydrate-binding proteins Galectins (Gals) in the combined processes of inflammation and aging contributing to bone fragility by exploring their potential as novel therapeutic targets for OP.

Bone fragility is the susceptibility to fracture due to poor bone strength. This condition is usually associated with aging, comorbidities, disability, poor quality of life, and increased mortality. International guidelines for the management of patients with bone fragility include a nutritional approach, mainly aiming at optimal protein, calcium, and vitamin D intakes. Several biomechanical features of the skeleton, such as bone mineral density (BMD), trabecular and cortical microarchitecture, seem to be positively influenced by micro- and macronutrient intake. Patients with major fragility fractures are usually poor consumers of dairy products, fruit, and vegetables as well as of nutrients modulating gut microbiota. The COVID-19 pandemic has further aggravated the health status of patients with skeletal fragility, also in terms of unhealthy dietary patterns that might adversely affect bone health. In this narrative review, we discuss the role of macro- and micronutrients in patients with bone fragility during the COVID-19 pandemic.